Invention Publication
- Patent Title: COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
-
Application No.: US18506606Application Date: 2023-11-10
-
Publication No.: US20240108616A1Publication Date: 2024-04-04
- Inventor: Deepak Sampath , Christian Klein , Wayne John Fairbrother , Sari L. Heitner Enschede , Rod A. Humerickhouse , Andrew W. Roberts , John F. Seymour
- Applicant: GENENTECH, INC. , HOFFMANN-LA ROCHE INC. , ABBVIE INC.
- Applicant Address: US CA South San Francisco
- Assignee: GENENTECH, INC.,HOFFMANN-LA ROCHE INC.,ABBVIE INC.
- Current Assignee: GENENTECH, INC.,HOFFMANN-LA ROCHE INC.,ABBVIE INC.
- Current Assignee Address: US CA South San Francisco; US NJ Little Falls; US IL North Chicago
- Main IPC: A61K31/496
- IPC: A61K31/496 ; A61K31/02 ; A61K31/04 ; A61K31/10 ; A61K31/18 ; A61K31/33 ; A61K31/436 ; A61K31/437 ; A61K31/4375 ; A61K31/45 ; A61K31/505 ; A61K31/63 ; A61K39/395
Abstract:
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Information query
IPC分类:
